Topic : Medications

Other Topics :

Lower dose may be feasible in older people

Chronic myelogenous leukemia typically affects people later in life, at an age when they may be at greater risk of medication-related side effects. Aging bodies don’t necessarily process medications as well, and the situation can be complicated by other medical conditions, such as hig
Continue Reading →

Sifting through nature’s harvest for solutions

Nature has long been the source of many of the pharmaceuticals used to treat various illnesses, including different types of cancer. An estimated 60% of all cancer drugs originate from natural products, such as trees, shrubs, fruits and vegetables, and marine animals. Perhaps one of t
Continue Reading →

Considering the options when starting treatment

Chronic myelogenous leukemia is now routinely treated with a tyrosine kinase inhibitor (TKI), a family of drugs that blocks leukemia signalling in the bone marrow and arrests the disease process. Three TKIs are approved for use in people newly diagnosed with chronic-phase CML: Gleevec
Continue Reading →

TKIs in people with liver or kidney disease

Clinical trials of medications generally exclude people with medical conditions other than the condition being studied, so little is known about whether these treatments are safe in a wide range of people. This issue is especially important in CML, because the disease affects older pe
Continue Reading →

Stopping your CML meds

“Treatment-free remission” is the hottest topic in CML these days, with a number of studies exploring whether some people are able to stop taking their medication.
Continue Reading →

Generic Gleevec – Is the same the same?

American Society of Hematology 57th Annual Meeting, Orlando FL, December 5-8, 2015 – Brand-name drugs are new therapies (or “me-too” drugs) that are rigorously tested before they are allowed on the market by regulatory bodies, such as the U.S. Food and Drug Administration or Hea
Continue Reading →

Treatment-free remission – how well do people do?

A new goal in treating CML is treatment-free remission (TFR). What this means is that CML is so deeply suppressed with treatment that the person is able to stop the medication altogether and the leukemia doesn’t return. The physical advantages of TFR will be obvious to anyone taking o
Continue Reading →

Treating CML early – a cautionary tale

It’s not always a simple matter to get access to the medications you need, but a delay in starting treatment for CML can jeopardize the success of therapy. This was shown in a recent study conducted in Bosnia, where people often face considerable red tape before they can start a
Continue Reading →

Current CML treatment studies in Canada

Chronic myelogenous leukemia is a hot area of medical research, in part because of the development of the first effective treatment (Gleevec) a decade ago and the insights about the biology of the disease that have resulted from that important discovery.
Continue Reading →

Comparing CML treatments

Many people with CML start treatment with a second-generation medication, such as Sprycel or Tasigna, because they more potently suppress the proliferation of leukemia cells. But how do these two medications compare?
Continue Reading →